In November 2004, Berger & Montague shareholders co-sponsored a well-received symposium in conjunction with the University of San Francisco School of Law on cutting edge antitrust issues in the pharmaceutical industry.  The symposium was attended by leading antitrust scholars and practitioners, including Prof. Herbert Hovenkamp.  The symposium specifically addressed important questions arising out of antitrust class actions that Berger & Montague has been prosecuting on behalf of direct purchasers of brand-name drugs against major pharmaceutical manufacturers for blocking the entry of less expensive competitor drugs.  The University of San Francisco Law Review published several significant articles written for the symposium, two of which were authored by Berger & Montague shareholders.  For instance, shareholders Eric L. Cramer and Daniel Berger published a piece entitled The Superiority of Direct Proof of Monopoly Power and Anticompetitive Effects in Antitrust Cases Involving Delayed Entry of Generic Drugs, 39 USF L. Rev. 81 (Fall 2004), and shareholder David Sorensen co-authored an article with Prof. Joshua Davis of the law school, entitled Chimerical Class Conflicts in Federal Antitrust Litigation: The Fox Guarding the Chicken House in Valley Drug, 39 USF L. Rev. 141 (Fall 2004).

Inquiries about the symposium or the articles should be addressed to Eric L. Cramer (215-875-3009) or David Sorensen (215-875-5705).